Monday, May 4, 2009

ZymoGenetics Licenses Products To Seattle Life Sciences

Seattle-based ZymoGenetics reported Monday that it has licensed the rights to eight of the firm's early stage product candidates to Seattle Life Sciences. Financial impact of the deal was not disclosed. According to Zymogenetics, it is entitled to equity in Seattle Life Sciences, in conjunction with SLS obtaining venture capital financing. The licensing came shortly after the firm cut 32 percent of its staff and cut its research activities, in a bid to cut its operating expenses.